



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07K</p>	<p>A2</p>	<p>(11) International Publication Number: WO 99/57133</p> <p>(43) International Publication Date: 11 November 1999 (11.11.99)</p>
<p>(21) International Application Number: PCT/BE99/00055</p> <p>(22) International Filing Date: 5 May 1999 (05.05.99)</p> <p>(30) Priority Data: 98201472.2 6 May 1998 (06.05.98) EP</p> <p>(71) Applicant (for all designated States except US): VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW [BE/BE]; Rijvisschestraat 120, B-9052 Zwijnaarde (BE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BEYAERT, Rudi [BE/BE]; Gentssteenweg 16, B-9750 Zingem (BE). HEYNINCK, Karen [BE/BE]; Koperstraat 1, B-9830 Sint-Martens-Latem (BE). FIERIS, Walter [BE/BE]; Beukendreef 3, B-9070 Destelbergen (BE).</p> <p>(74) Common Representative: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW; Rijvisschestraat 120, B-9052 Zwijnaarde (BE).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: NOVEL INHIBITORS OF NF-κB ACTIVATION</p>		
<p>(57) Abstract</p> <p>The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-κB) activating pathway useful in the treatment of NF-κB related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signalling pathway and are therefore more specific than IκB.</p>		